Rapid Infectious Disease Testing Picks Up Speed
Executive Summary
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
You may also be interested in...
Diagnostics In 2016: From Alere To Zika
No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.
Singulex: Next-Gen Immunodiagnostics
Singulex originally developed its Single Molecule Counting technology for research applications, but it is poised to launch a clinical diagnostics tool that incorporates the highly sensitive technology.
Infectious Disease Companies Catch More Investors
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.